Skip to content It’s an investigational injectable medication known as a “triple agonist” — it targets three hormone receptors (GLP-1, GIP, and glucagon) instead of just one or two, unlike earlier drugs such as semaglutide (Wegovy) or tirzepatide (Zepbound). It’s developed by Eli Lilly and is not yet approved by the FDA — it remains investigational.
